Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash & Current Investments: 2019-2025

Historic Cash & Current Investments for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $672.6 million.

  • Harmony Biosciences Holdings' Cash & Current Investments rose 53.97% to $672.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 31.77%. This contributed to the annual value of $467.2 million for FY2024, which is 16.70% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Cash & Current Investments of $672.6 million as of Q3 2025, which was up 18.98% from $565.3 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Cash & Current Investments' 5-year high stood at $672.6 million during Q3 2025, with a 5-year trough of $141.2 million in Q1 2021.
  • Over the past 3 years, Harmony Biosciences Holdings' median Cash & Current Investments value was $424.1 million (recorded in 2024), while the average stood at $455.3 million.
  • In the last 5 years, Harmony Biosciences Holdings' Cash & Current Investments fell by 14.45% in 2021 and then skyrocketed by 62.23% in 2022.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' Cash & Current Investments stood at $234.3 million in 2021, then surged by 56.29% to $366.2 million in 2022, then climbed by 9.32% to $400.3 million in 2023, then grew by 16.70% to $467.2 million in 2024, then surged by 53.97% to $672.6 million in 2025.
  • Its Cash & Current Investments was $672.6 million in Q3 2025, compared to $565.3 million in Q2 2025 and $507.0 million in Q1 2025.